|Published||Report Code||Available Format||Pages|
Valued at $2,402.3 million in 2019, the global blood screening market is projected to witness a CAGR of 8.1% during the forecast period (2020–2030). The key factors driving the industry are the stringent regulations regarding contaminated blood, rising prevalence of infectious, respiratory, and chronic diseases, improvements in the blood screening technology, rising number of donors, and increasing healthcare expenditure.
The kits & reagents category dominated the blood screening market in 2019, on the basis of product type. This is because of the usage of these products during the first stage of the blood screening procedure and easy availability of numerous reagents. Further, the preference for the fast, specific, and reliable detection of transfusion-transmissible diseases (TTD) is also rising, which further drives the adoption of these products.
During the forecast period, the nucleic acid technology (NAT) classification is expected to witness the fastest blood screening market growth, based on technology. This is because this technology is more popular among testing laboratories and blood banks, due to its higher sensitivity compared to others.
The human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) division, under the disease type segment, would hold the largest share in the blood screening market in 2030. This is because before giving blood to someone, it is mandatorily screened for HIV/AIDS, with which 37.9 million people were suffering around the world in 2018, according to the World Health Organization (WHO).
In 2019, blood banks were the largest category in the market, based on end user, as the blood donation activities, organ transplant surgeries, and awareness about the dangers of contaminated blood are increasing around the world.
During the historical period (2014–2019), North America was the largest blood screening market, due to the high incidence of respiratory and infectious diseases in the region. For instance, the region has the highest COVID-19 case and death count, of around 560,000 and 22,100, respectively, as of April 13, 2020. Additionally, market players are launching new products in North America, such as those specifically made for COVID testing, including the CoronaCheck antibody test kit developed by BioResponse. Further, governments are promoting the use of advanced screening products; for instance, the Canadian government encourages the adoption of NAT-based kits and assays for the detection of viruses in the blood, even when the viral genetic material is low and the antibodies haven’t been produced in the infected patient.
Among the prominent trends in the blood screening market is mergers and acquisitions among the key players. For instance, in January 2020, F. Hoffmann-La Roche Ltd. and Illumina Inc. began a 15-year, non-exclusive partnership to promote the usage of distributable next-generation sequencing (NGS)-based oncology testing. Similarly, in April 2019, Ortho-Clinical Diagnostics Inc. introduced its D-Dimer assay under its MicroTip partnership assay program, in collaboration with Diazyme Laboratories Inc.
The key growth driver for the blood screening market is the stringent regulatory landscape which seeks to minimize the chances of blood contamination. As per the WHO, 123 countries had policies regarding coordinated blood collection, testing, processing, storage, and distribution, in 2015, while 104 nations had policies specifically related to the safety of blood transfusion and quality of the transfused blood. With the increasing number of blood donations, screening activities are also going up. The WHO says that 117.4 million units of blood are donated around the world every year, of which 100 million units are collected at 12,700 blood centers in 170 countries.
In recent years, players in the blood screening market have launched a number of new and advanced products, in order to stay ahead of their competitors.
For instance, in September 2019, F. Hoffmann-La Roche Ltd. announced that it received approval from the USFDA for the cobas Babesia test for use on the cobas 6800/8800 systems for individual blood donation testing. It is a commercially available whole blood test to screen donations and follows May 2019 FDA-updated industry guideline recommending screening and testing for Babesia to reduce the risk of transmitting the parasite through transfusions.
Similarly, in February 2019, the FDA approved Grifols S.A.’s Procleix Babesia assay, which can detect ribosomal ribonucleic acid (RNA) of four Babesia species: B. duncani, B. microti, B. venatorum, and B. divergens. The assay can detect these parasites in individual or 16 pooled lysed samples of whole blood or individual blood components.
The major global blood screening market players are Abbott Laboratories, Bio-Rad Laboratories Inc., Becton, Dickinson and Company, General Electric Company, Thermo Fisher Scientific Inc., Merck KGaA, Siemens AG, Grifols S.A., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A, J. Mitra & Co. Pvt. Ltd., Bio-Techne Corporation, Trinity Biotech plc, Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH (GFE), F. Hoffmann-La Roche Ltd., Danaher Corporation, PerkinElmer Inc., and bioMérieux SA.
The blood screening market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.
Based on Product Type
Based on Technology
Based on Disease Type
Based on End User